Navigation Links
ZYBAN, The smoking cessation drug marked for its adverse reactions

GlaxoSmithKline's smoking cessation drug Zyban, which is being taken by over 5 million people world wide, is held responsilble for a raise in the suspected adverse reactions due to drug intake in UK.

Pharmacovigilance statistics of MCA has shown a raise of about 37% more adverse reactions so called "yellow cards" during the period of January to April 2001 compared to that of last years. MCA spokeswoman explained that the main factor responsible for such an increase in the "yellow cards" is the smoking cessation aid Zyban. However, from January to April 2001 Zyban "accounted for 32% of all yellow cards" she added.

Over 5000 adverse reactions including 40 deaths relating to Zyban has been reported.

As a result of this, the UK Committee on Safety of Medicines issued a statement to doctors and patients recommending change in the starting doses of Zyban and to use the drug only on compelling reasons for the patients at risk of seizures.

GSK spokesmam in response to this commented that Zyban is a prescription-only medicine that must be taken appropriately and not by patients with a history of seizures. He also added that the rate of seizures seen was consistent with the clinical trials experience.
'"/>




Page: 1

Related medicine news :

1. Vaccine to quit smoking?
2. A boost to quit smoking
3. Quitting smoking stops lung decline
4. Passive smoking affects respiratory system
5. Stop smoking and reduce weight
6. Teens listen to parents about smoking
7. Teen smoking declines
8. Cancer patients pursue smoking inspite of risks
9. A new herbal therapy to quit smoking
10. Watching television linked to smoking
11. Quit smoking after cancer diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ZYBAN The smoking cessation drug marked for its adverse reactions

(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where different ... signatures within the same cancer. Such differences could ... strategies. , Firstly they confirmed the mutual exclusivity ... or BRAF mutation. Secondly, they found that lung ... that specific mutation present uniformly throughout the tumour, ...
(Date:4/23/2014)... bottom of Alzheimer,s disease has been a rapidly ... In the latest crook in the research road, ... interaction between proteins associated with the disease. The ... Chemical Neuroscience , could have important implications for ... Nieznanski and colleagues explain that for years, research ...
(Date:4/22/2014)... (Chicago) A recently FDA-approved device has been shown ... as much as 50 percent. When coupled with an ... Rush, the device facilitated the complete elimination of seizures ... in the decade-long clinical trials. , That,s good news ... in the U.S. living with epilepsy whose seizures can,t ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
(Date:4/22/2014)... Bethesda, MD, April 22, 2014: The Association for ... The Journal of Molecular Diagnostics on ... the baccalaureate and master,s levels of education. The ... (MLS) Curriculum Task Force of the AMP Training ... the critical need of educating future medical laboratory ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... blood vessel walls can vary among individuals depending on factors ... research at UC Davis. The new research reinforces the ... linings that can lead to heart disease and strokes. ... cholesterol," known to increase risk of inflammation of the endothelium, ...
... Salamon HealthDay Reporter , THURSDAY, Feb. 17 (HealthDay ... weeks early has no discernible impact on babies, a new ... than their full-term peers and those delays may affect their ... term and 1,200 late preterm infants -- those born between ...
... 2011) Two studies published in the current issue ... islet cell transplantation for treating diabetes. Researchers in Milan, ... in diabetic therapy and islet cell regeneration and Canadian ... in vitro. Both studies are in the ...
... Feb. 17 (HealthDay News) -- The area of the brain ... that suggests the brain is a "task machine" instead of ... brain scans, the researchers measured neural activity in eight blind ... blind since birth, showed activity in the exact same part ...
... cell phone use does not appear to increase the ... a study by University of Manchester scientists suggests. ... Office of National Statistics to look at trends in ... 1998 and 2007. The study, published in the ...
... urban public housing spend more time playing outdoors than ... Columbia University and Princeton University. Contrary to ... living in poorer circumstances would be playing outside less, ... played outside 13 percent more per day, on average, ...
Cached Medicine News:Health News:Study reinforces link between obesity, high-fat meals and heart disease 2Health News:Delivery Even a Bit Early May Mean Developmental Delays 2Health News:Delivery Even a Bit Early May Mean Developmental Delays 3Health News:Researchers work at the frontiers of islet cell transplantation 2Health News:Researchers work at the frontiers of islet cell transplantation 3Health News:Cell-phone use not related to increased brain cancer risk 2Health News:Children in public housing play outdoors more 2
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... TRIANGLE PARK, N.C., Jan. 6, 2011 CeNeRx BioPharma, Inc., today ... new formulation of TriRima ™, the company,s novel antidepressant in ... it will be presenting at Biotech Showcase™ ... 11:00 AM PST. TriRima is a member ...
... Pharmasset, Inc. (Nasdaq: VRUS ), announced today positive ... HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase ... dual nucleotide study.   Pipeline Update and ... PSI-7977 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV) in a ...
Cached Medicine Technology:CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression 2CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression 3Pharmasset Reports Positive Results from its HCV Clinical Programs 2Pharmasset Reports Positive Results from its HCV Clinical Programs 3Pharmasset Reports Positive Results from its HCV Clinical Programs 4Pharmasset Reports Positive Results from its HCV Clinical Programs 5Pharmasset Reports Positive Results from its HCV Clinical Programs 6
... a sterile nonpyrogenic, transparent viscoelastic solution of ... mg/mL of high molecular weight (greater than ... physiological saline. In the limit of zero ... (105 Pa s) at 25C, and the ...
Orbital Retractor, schepens Retractors, overall length:154mm....
... places fast and accurate visual ... Utilising standard computer hardware and ... with new testing and display ... integrated into a modern ophthalmic ...
... With a test capability extending to 80, ... a patient's visual field, allowing peripheral defects ... field to be explored. Practice Management Integration ... practice. With the Medmont Studio package the ...
Medicine Products: